

# **2020 ANTIBACTERIAL AGENTS IN CLINICAL AND PRECLINICAL DEVELOPMENT**

an overview and analysis



World Health  
Organization



# **2020 ANTIBACTERIAL AGENTS IN CLINICAL AND PRECLINICAL DEVELOPMENT**

an overview and analysis



World Health  
Organization

2020 Antibacterial agents in clinical and preclinical development: an overview and analysis

ISBN 978-92-4-002130-3 (electronic version)

ISBN 978-92-4-002131-0 (print version)

**© World Health Organization 2021**

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization (<http://www.wipo.int/amc/en/mediation/rules/>).

**Suggested citation.** 2020 Antibacterial agents in clinical and preclinical development: an overview and analysis. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Design and layout by Phoenix Design Aid

# Contents

Acknowledgements	vi
Abbreviations and acronyms	vii
Executive summary	viii
<b>1. INTRODUCTION</b>	<b>1</b>
<b>2. AGENTS THAT OBTAINED MARKET AUTHORIZATION SINCE 1 JULY 2017</b>	<b>2</b>
<b>3. CLINICAL ANTIBACTERIAL PIPELINE</b>	<b>4</b>
3.1 Antibiotics being developed against WHO priority pathogens	5
3.1.1 <i>β-Lactams</i>	7
3.1.2 <i>Tetracyclines</i>	10
3.1.3 <i>Aminoglycosides</i>	10
3.1.4 <i>Topoisomerase inhibitors</i>	11
3.1.5 <i>FabI inhibitor</i>	11
3.1.6 <i>FtsZ inhibitor</i>	12
3.1.7 <i>Oxazolidinones</i>	12
3.1.8 <i>Macrolides and ketolides</i>	12
3.1.9 <i>Antibiotic hybrids</i>	13
3.1.10 <i>Polymyxins</i>	13
3.2 Agents in development for treating TB infections	13
3.3 Agents in development for treating <i>C. difficile</i> infections	15
3.4 Non-traditional antibacterials	17
3.4.1 <i>Antibodies</i>	18
3.4.2 <i>Bacteriophages and phage-derived enzymes</i>	20
3.4.3 <i>Microbiome-modulating agents</i>	20
3.4.4 <i>Immunomodulating agents</i>	22
3.4.5 <i>Miscellaneous</i>	22
3.5 Agents that are not under active development or for which there is no recent information	23
<b>4. PRECLINICAL ANTIBACTERIAL PIPELINE</b>	<b>24</b>
4.1 Individual entities developing preclinical projects	25
4.2 Categorization of preclinical agents	26

<b>5. DISCUSSION</b>	<b>28</b>
5.1 New agents mainly derivatives of existing classes	28
5.2 The clinical “traditional” pipeline is still insufficient against priority pathogens	28
5.3 Innovation remains a challenge for Gram-negatives	29
5.4 Diversity in non-traditional approaches	29
5.5 A dynamic preclinical pipeline database	30
5.6 The pipeline outlook is slightly improved but remains unfavourable	30
<b>6. METHODS</b>	<b>31</b>
6.1 Clinical pipeline analysis	31
6.1.1 Scope and inclusion/exclusion criteria	31
6.1.2 Search strategy	32
6.1.3 Assessment of activity against priority pathogens and innovation	32
6.2 Preclinical pipeline review	33
6.2.1 Scope and inclusion/exclusion criteria	33
6.2.2 Data collection	34
6.3 Methodological considerations	34
6.3.1 Variable data quality	34
6.3.2 Limitations	34
<b>7. REFERENCES</b>	<b>36</b>
Annex 1. Declaration of interests of advisory group members	41
Annex 2. Background information on Phase 3 antibacterial products	43
1. Sulopenem	43
2. Durlobactam (ETX-2514) + sulbactam	47
3. Taniborbactam (VNRX-5133) + cefepime	49
4. Enmetazobactam (AAI-101) + cefepime	51
5. Zoliflodacin	53
6. Gepotidacin	55
7. Ridinilazole	57

Table 1.	Antibiotics that gained market authorization between 1 July 2017 and 1 September 2020	3
Table 2.	Antibiotics being developed against WHO priority pathogens	5
Table 3.	Expected activity of $\beta$ -lactams and $\beta$ -lactam/BLI combinations against common $\beta$ -lactamases	7
Table 4.	Antibiotics for the treatment of TB and non-tuberculous mycobacteria in clinical development	14
Table 5.	Antibiotics (small molecules) for the treatment of <i>C. difficile</i> infections in clinical development	16
Table 6.	Non-traditional antibacterial agents in clinical development	17
Table 7.	Agents not under active development or for which there is no recent information	23
Table 8.	Distribution of preclinical programmes by mode of action and development stages	26
Table 9.	Structure and development goals of traditional and non-traditional antibacterials	31
Fig. 1.	Traditional and non-traditional antibacterials in clinical development (Phases 1–3)	x
Fig. 2.	Geographical distribution of the 162 developers	25
Fig. 3.	Categorization of entities that responded to the 2020 data call	26
Fig. 4.	Distribution of preclinical programmes by antibacterial agent and vaccine category	26
Fig. 5.	Pathogens targeted by a single pathogen target product	27
Fig. 6.	Summary of antibiotics in the clinical pipeline targeting WHO priority pathogens	29
Fig. 7.	Summary of non-traditional antibacterials in the clinical pipeline	30
Fig. 8.	Traditional drug development phases showing the preclinical phases included in this report in red	33

# Acknowledgements

This publication was prepared by Sarah Paulin (WHO, Antimicrobial Resistance Division) with support from Mark Butler (WHO Consultant), Hatim Sati (WHO Consultant), Richard Alm (WHO Consultant) and Laila Al-Sulaiman (WHO Intern) under the direct supervision of Peter Beyer (WHO, Antimicrobial Resistance Division) and the overall direction of Haileyesus Getahun (WHO, Antimicrobial Resistance Division). Administrative support was provided by Sandra Kotur Corliss (WHO, Antimicrobial Resistance Division).

We would like to thank the members of the advisory group, which met virtually on 23–24 November 2020 to discuss and assess the antibacterial agents included in this report. The advisory group consisted of:

- Cesar Arias, Professor, University of Texas Health Science Center, Houston, United States of America, and Founder and Scientific Advisor, Molecular Genetics and Antimicrobial Resistance Unit/International Center for Microbial Genomics, Universidad El Bosque, Colombia.
- Lloyd Czaplewski, Director, Chemical Biology Ventures, United Kingdom of Great Britain and Northern Ireland.
- Prabha Fernandes, Chair of the Scientific Advisory Committee, Global Antibiotic Research and Development Partnership (GARDP), Switzerland, and independent consultant.
- François Franceschi, Project Leader, Asset Evaluation and Development, GARDP, Switzerland (observer).
- Stephan Harbarth, Full Professor, Division of Infectious Diseases and Infection Control Programme, Geneva University Hospitals, WHO Collaborating Centre, Switzerland.
- Jennie Hood, Global AMR R&D Hub, Germany (observer).
- Roman Kozlov, Rector, Smolensk State Medical University, Russian Federation.
- Christian Lienhardt, Research Director, Institute for Research on Sustainable Development and University of Montpellier, France.
- Norio Ohmagari, Director, Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan.
- Mical Paul, Director, Infectious Diseases Institute, Rambam Health Care Campus, Israel.
- John H. Rex, Chief Medical Officer, F2G Ltd, USA.
- Mike Sharland, Chair of the WHO Antibiotic Working Group of the EML/EMLc, and St George's University London, UK (observer).
- Lynn Silver, Owner, LL Silver Consulting, USA.
- Melvin Spigelman, President and Chief Executive Officer, Global Alliance for TB Drug Development (TB Alliance), USA.
- Guy Thwaites, Director, Oxford University Clinical Research Unit (OUCRU), Viet Nam.

We also thank Roman Kozlov and Norio Ohmagari for providing data from the Russian Federation and Japan, respectively.

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_23966](https://www.yunbaogao.cn/report/index/report?reportId=5_23966)

